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A Ab bs st tr ra ac ct t
Renal clear cell carcinomas represent about 3% of all visceral cancers and account for approximately 85% of
renal cancers in adults. Environmental and genetic factors are involved in the development of renal cancer.
Although to date there are 19 hereditary syndromes described in which renal cell cancer may occur, only four
syndromes with an unequivocal genetic predisposition to renal cell carcinoma have been identified: VHL syndrome
(mutations in the VHL gene), hereditary clear cell carcinoma (translocations t(3:8), t(2:3)), hereditary papillary
carcinoma (mutations in the MET protooncogene) and tuberous sclerosis (mutations in the TSC1 and TSC2
genes). Little is known genetically about the other forms of familial renal cell cancer. Since there is a growing
awareness about the necessity of early intervention, clinical criteria have been developed that aid in the
identification of hereditary forms of renal cancer. The aim of the current study was to identify minimal inclusion
criteria so that nuclear pedigree families can be ascertained for risk assessment and/or kidney tumour screening.
The results reveal that inclusion features described herein, such as (a) renal clear cell cancer diagnosed before
55 years of age, and (b) renal clear cell cancer and gastric cancer or lung cancer among first degree relatives,
are useful in identifying suspected hereditary clear cell renal cancer patients.
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I In nt tr ro od du uc ct ti io on n
Renal clear cell carcinomas represent about 3%
of all visceral cancers and account for 85% of renal
cancers in adults. The tumours occur most often in
older individuals, usually in the sixth and seventh
decades of life, and are often diagnosed at
incurable stages [1]. In Western countries the
frequency of renal cancer remains relatively high,
there being approximately 30,000 new cases and
12,000 deaths per year from the disease [1]. The
causes of kidney cancer are believed to be
environmental (such as cigarette smoking, asbestos,
petroleum products, heavy metals, unopposed
oestrogen therapy, hypertension and obesity),
genetic or a mixture of both [1]. To date there are
19 hereditary syndromes described in which renal
cell cancer may occur (Table 1). H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2005; 3(3) 130
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The identification of genetic predispositions to renal
cell cancer remains a priority since knowledge about
the underlying molecular genetic basis of the disease
will allow for a better understanding of the mechanisms
giving rise to the disease and, perhaps more
importantly, allow for the identification of individuals
who are at risk of disease development.
There are two aspects of these criteria that can be
problematic in the clinical setting with respect to the
identification of familial renal cell cancer patients. The
first is the difficulty in fulfilling criteria in countries where
large families and extensive pedigrees are impossible
to identify, for whatever reason, even though the
incidence of hereditary renal cell cancer may be quite
high. Second, the criteria do not take into consideration
the existence of family cancer syndromes where renal
cell cancer may occur in association with an extra-
gastric malignancy.
From a clinical perspective, there is a necessity to
be able to identify hereditary renal cell cancer families
with a minimum set of criteria that will provide a high
likelihood of ascertainment. The aim of this study was
to determine whether a minimum set of criteria could
be established to identify suspected hereditary renal
cell cancer patients when there is restricted information
about the familial occurrence of disease.
T Ta ab bl le e   1 1. .   Genetic syndromes characterised by an increased risk of renal cancer (Familial Cancer Database - FACD, http://facd.uicc.org )
S Sy yn nd dr ro om me e H Hi is st to ol lo og gi ic ca al l    G Ge en ne e M Mo od de e    F Fr re eq qu ue en nc cy y    R Re ef fe er re en nc ce es s
t ty yp pe e   o of f   r re en na al l   c ca an nc ce er r o of f   i in nh he er ri it ta an nc ce e o of f   s sy yn nd dr ro om me es s
A. VHL Clear cell carcinoma VHL AD 1:36000 2, 3, 4, 5, 6, 7
B. Hereditary clear Clear cell  FHIT? AD 4 families 8, 9, 10, 11, 12,
cell carcinoma carcinoma TRC? reported 13, 14, 15, 16, 17, 
18, 19
Papillary carcinoma MET AD ? 20, 21, 22, 23, 24
C. Lynch  Urothelial hMSH2 AD 1:2000 25, 26, 27, 28, 29, 30
(HNPCC) carcinoma hMLH1
D. Tuberous  Clear cell TSC1 AD ? 31, 32, 33, 34, 35
sclerosis carcinoma TSC2
Papillary carcinoma
E. Bean ? ? AD simple families 36
F. Cowden ? PTEN AD ? 37
G. Gorlin ? PTCH AD ? 38
H. Fanconi anaemia  ? FANCA AR ? 39, 40, 41
FANCC
FANCD
FANCG
FANCE
I. MEN1 Oncocytoma MEN1 AD ? 42, 43, 44
J. Reed ? ? AD simple families 45
K. Werner ? WRN AR simple families 46, 47, 48, 49
L. Birt-Hogg-Dube ? ? AD simple families 50
M. Syndrome of  ? CRAC1 AD one family 51
multiple adenomas 
and carcinoma 
of large bowel
N. 'Diffuse  Tubulo-papillary  ? de novo two cases  52
tubulocystic renal  carcinoma 
hyperplasia with 
renal cell 
carcinoma'H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2005; 3(3) 131
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P Pa at ti ie en nt ts s   a an nd d   m me et th ho od ds s
A total of 146 clear cell renal carcinoma (CCRC)
patients comprising 3 groups were enrolled in the study.
Group A (familial renal cancer): comprising 46
patients affected by CCRC from 22 randomly selected
families with at least two renal cancers among first or
second degree relatives, independent of age at
diagnosis of tumours. All families were registered in
the International Hereditary Cancer Centre in Szczecin.
Group A1 (nuclear pedigree): comprising 25
patients affected by CCRC from Group A. None of the
parents of these patients have been diagnosed as
affected with renal cell cancer. 
Group B: a total of 100 individuals diagnosed with
CCRC between the years 1993 and 1997 irrespective
of family history were collected from the city of Szczecin
(total population 400,000).
The following inclusion features (IF) for the
identification of suspected hereditary forms of clear cell
renal cancer were used and compared against one
another for their sensitivity and specificity:
IF 1: at least one of the parents of the patient with
CCRC was affected by lung cancer
IF 2: at least one of the parents of the patient with
CCRC was affected by gastric cancer 
IF 3: CCRC diagnosed at the age of 45 years or younger
IF 4: CCRC diagnosed at the age of 50 years or younger 
IF 5: CCRC diagnosed at the age of 55 years or younger
S St ta at ti is st ti ic ca al l  a an na al ly ys si is s
Univariate statistical analysis (Chi-squared, odds
ratio (OR), and sensitivity and specificity of selection
were performed using the SAS and LOGIT programs.
R Re es su ul lt ts s
The comparison of the five IFs was undertaken to
identify the most consistent criteria that can be
employed in a clinical setting for the identification of
suspected hereditary renal cell cancer, based on
nuclear pedigree data. The first comparison was
between Group A (associated with a genetic
predisposition to disease) compared to unselected
cases from Group B (Table 2). The results indicate that
all inclusion features are more frequent in Group A
(OR 1.62-4.88). There is no statistically significant
difference for inclusion features IF1, IF2 and IF3.
The second comparison was performed between
Group A1 and Group B (Table 3). The results indicate
that there is a very strong correlation between hereditary
(familial) predisposition to CCRC and occurrence of
at least one of the following IFs: IF1, IF2 or IF5 - OR
13.4; p<0.00001.
D Di is sc cu us ss si io on n
The recognition of features that can be used for the
identification of familial predispositions to CCRC in
situations where extensive pedigree analysis is unknown
or impossible to ascertain but the prevalence of the
disease is relatively high in the population will aid in
the identification of individuals at increased risk of
developing CCRC. 
By using the criteria described herein and the
consequent recognition of significant odds ratios for
some of the inclusion features to identify CCRC
families, we believe that the identification of additional
genes associated with this malignancy will be expedited.
Of particular interest are the odds ratio values for
the inclusion features IF5 between groups A1 and B and
IF 1 between groups A1 and B, which were relatively
high (6.21 and 6.09, respectively). Since these inclusion
features are significant we have a relatively high degree
of confidence that the reported observations are not
biased and are an accurate reflection of the validity of
our approach for the identification of hereditary CCRC
families. Indeed, these criteria have been tested in our
T Ta ab bl le e   2 2. .
C Cr ri it te er ri ia a G Gr ro ou up p G Gr ro ou up p O OR R C CI I S Se en ns si it ti iv vi it ty y S Sp pe ec ci if fi ic ci it ty y P P
A A    B B
( (n n= =4 46 6) ) ( (n n= =1 10 00 0) )
IF1 5 7 1.62 0.5-5.2 10.87 93.00 0.4291
IF2 7 6 2.81 0.9-8.5 15.22 94.00 0.0693
IF3 7 6 2.81 0.9-8.5 15.22 94.00 0.0693
IF4 15 12 3.54 1.5-8.3 32.61 88.00 0.0029
IF5 23 17 4.88 2.3-10.6 50.00 83.00 0.000H He er re ed diit ta ar ry y  C Ca an nc ce er r  iin n  C Clliin niic ca all  P Pr ra ac ct tiic ce e 2005; 3(3) 132
outpatient clinics to successfully identify hereditary
CCRC. Therefore if we have families matching IF1 or
IF2 or IF5, we are confident that a diagnosis of familial
CCRC can be made. 
At present it seems reasonable to offer the option
of ultrasonography examination to all individuals
identified by the use of our inclusion features beginning
at the age of 5 to 10 years before the youngest CCRC
identified within the patient’s family. Such surveillance
should only be an option and not a recommendation
because the efficiency of such management procedures
has not been rigorously determined to reduce morbidity
and/or mortality. With respect to surveillance the real
value of this will have to be established by studies on
large cohorts of individuals from families matching
pedigree and clinical criteria of suspected hereditary
CCRC with identified constitutional DNA variants
associated with genetic predispositions. 
So far, the list of genetic changes associated with
CCRC is somewhat limited but should be extended in
the near future as more knowledge is gained about
the genetic factors associated with altered CCRC
predisposition.
In summary, we advocate the use of our criteria for
suspected hereditary clear cell renal cancer identified
in this report in order to:
a. offer an ultrasound examination option,
b. create repositories of nuclear clear cell renal cancer
families for future studies on the efficiency of
surveillance for individuals with genetic
predispositions to renal cancer,
c. perform further studies to aid in the identification of
genetic factors associated with CCRC.
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